MGI Tech Co., Ltd.

SHSE:688114 Stock Report

Market Cap: CN¥20.2b

MGI Tech Valuation

Is 688114 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688114 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688114 (CN¥46.9) is trading above our estimate of fair value (CN¥33.43)

Significantly Below Fair Value: 688114 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688114?

Key metric: As 688114 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688114. This is calculated by dividing 688114's market cap by their current revenue.
What is 688114's PS Ratio?
PS Ratio7.5x
SalesCN¥2.58b
Market CapCN¥20.22b

Price to Sales Ratio vs Peers

How does 688114's PS Ratio compare to its peers?

The above table shows the PS ratio for 688114 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
300463 Maccura BiotechnologyLtd
3.1x13.2%CN¥8.5b
603108 Shanghai Runda Medical Technology
1.3xn/aCN¥11.1b
603127 Joinn Laboratories(China)Co.Ltd
6x12.3%CN¥11.9b
300347 Hangzhou Tigermed Consulting
7.7x13.3%CN¥48.7b
688114 MGI Tech
7.5x11.4%CN¥19.3b

Price-To-Sales vs Peers: 688114 is expensive based on its Price-To-Sales Ratio (7.5x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does 688114's PS Ratio compare vs other companies in the CN Life Sciences Industry?

0 CompaniesPrice / SalesEstimated GrowthMarket Cap
No more companies available in this PS range
688114 7.5xIndustry Avg. 4.9xNo. of Companies5PS02.85.68.411.214+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 688114 is expensive based on its Price-To-Sales Ratio (7.5x) compared to the CN Life Sciences industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is 688114's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688114 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ratio4.5x

Price-To-Sales vs Fair Ratio: 688114 is expensive based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688114 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥46.90
CN¥59.17
+26.2%
24.1%CN¥85.20CN¥42.01n/a5
Nov ’25CN¥48.17
CN¥60.48
+25.6%
26.0%CN¥85.20CN¥42.01n/a4
Oct ’25CN¥50.99
CN¥60.48
+18.6%
25.8%CN¥85.20CN¥42.01n/a4
Sep ’25CN¥40.05
CN¥60.48
+51.0%
25.8%CN¥85.20CN¥42.01n/a4
Aug ’25CN¥43.77
CN¥77.65
+77.4%
20.7%CN¥93.00CN¥50.70n/a4
Jul ’25CN¥47.93
CN¥83.09
+73.3%
21.7%CN¥104.83CN¥50.70n/a5
Jun ’25CN¥50.17
CN¥83.09
+65.6%
21.7%CN¥104.83CN¥50.70n/a5
May ’25CN¥58.20
CN¥83.09
+42.8%
21.7%CN¥104.83CN¥50.70n/a5
Apr ’25CN¥59.32
CN¥98.40
+65.9%
12.0%CN¥110.00CN¥77.79n/a5
Mar ’25CN¥68.96
CN¥98.40
+42.7%
12.0%CN¥110.00CN¥77.79n/a5
Feb ’25CN¥68.46
CN¥98.40
+43.7%
12.0%CN¥110.00CN¥77.79n/a5
Jan ’25CN¥86.02
CN¥100.20
+16.5%
11.5%CN¥110.00CN¥77.79n/a5
Dec ’24CN¥94.00
CN¥100.20
+6.6%
11.5%CN¥110.00CN¥77.79n/a5
Nov ’24CN¥80.15
CN¥100.20
+25.0%
11.5%CN¥110.00CN¥77.79CN¥48.175
Oct ’24CN¥74.88
CN¥104.39
+39.4%
9.7%CN¥117.86CN¥87.28CN¥50.995
Sep ’24CN¥78.27
CN¥104.39
+33.4%
9.7%CN¥117.86CN¥87.28CN¥40.055
Aug ’24CN¥88.21
CN¥103.76
+17.6%
6.2%CN¥110.00CN¥91.62CN¥43.775
Jul ’24CN¥86.56
CN¥103.76
+19.9%
6.2%CN¥110.00CN¥91.62CN¥47.935
Jun ’24CN¥87.88
CN¥103.49
+17.8%
6.9%CN¥110.00CN¥91.62CN¥50.174
May ’24CN¥80.14
CN¥111.49
+39.1%
15.9%CN¥140.00CN¥91.62CN¥58.204
Apr ’24CN¥95.10
CN¥135.51
+42.5%
11.2%CN¥151.40CN¥115.14CN¥59.323
Mar ’24CN¥102.30
CN¥135.51
+32.5%
11.2%CN¥151.40CN¥115.14CN¥68.963
Feb ’24CN¥115.30
CN¥135.51
+17.5%
11.2%CN¥151.40CN¥115.14CN¥68.463
Jan ’24CN¥111.11
CN¥145.70
+31.1%
3.9%CN¥151.40CN¥140.00CN¥86.022
Dec ’23CN¥112.63
CN¥145.70
+29.4%
3.9%CN¥151.40CN¥140.00CN¥94.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

7D

3.7%

1Y

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

7D

-1.8%

1Y

13.3%